Dianthus Therapeutics Inc (DNTH) Shares Decline Despite Market Challenges

Dianthus Therapeutics Inc (NASDAQ: DNTH)’s stock price has dropped by -10.20 in relation to previous closing price of 29.72. Nevertheless, the company has seen a loss of -13.88% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-26 that Invest in growth stocks such as American Eagle Outfitters (AEO), Abercrombie & Fitch (ANF), Cimpress (CMPR), Dianthus Therapeutics (DNTH) and NVIDIA (NVDA) as the stock market is well-poised to scale upward.

Is It Worth Investing in Dianthus Therapeutics Inc (NASDAQ: DNTH) Right Now?

Company’s 36-month beta value is 1.70.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The public float for DNTH is 21.52M, and currently, short sellers hold a 4.95% ratio of that floaft. The average trading volume of DNTH on April 03, 2024 was 136.14K shares.

DNTH’s Market Performance

DNTH’s stock has seen a -13.88% decrease for the week, with a 3.65% rise in the past month and a 156.63% gain in the past quarter. The volatility ratio for the week is 7.61%, and the volatility levels for the past 30 days are at 8.76% for Dianthus Therapeutics Inc The simple moving average for the past 20 days is -3.42% for DNTH’s stock, with a 79.33% simple moving average for the past 200 days.

Analysts’ Opinion of DNTH

Many brokerage firms have already submitted their reports for DNTH stocks, with Stifel repeating the rating for DNTH by listing it as a “Buy.” The predicted price for DNTH in the upcoming period, according to Stifel is $44 based on the research report published on February 15, 2024 of the current year 2024.

Jefferies, on the other hand, stated in their research note that they expect to see DNTH reach a price target of $22. The rating they have provided for DNTH stocks is “Buy” according to the report published on December 26th, 2023.

Wedbush gave a rating of “Outperform” to DNTH, setting the target price at $23 in the report published on November 22nd of the previous year.

DNTH Trading at 10.68% from the 50-Day Moving Average

After a stumble in the market that brought DNTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.97% of loss for the given period.

Volatility was left at 8.76%, however, over the last 30 days, the volatility rate increased by 7.61%, as shares surge +4.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +123.35% upper at present.

During the last 5 trading sessions, DNTH fell by -13.88%, which changed the moving average for the period of 200-days by +148.64% in comparison to the 20-day moving average, which settled at $27.70. In addition, Dianthus Therapeutics Inc saw 156.63% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at DNTH starting from Fairmount Funds Management LLC, who purchase 24,670 shares at the price of $13.63 back on Sep 29 ’23. After this action, Fairmount Funds Management LLC now owns 1,928,503 shares of Dianthus Therapeutics Inc, valued at $336,252 using the latest closing price.

Fairmount Funds Management LLC, the Director of Dianthus Therapeutics Inc, purchase 30,000 shares at $13.15 during a trade that took place back on Sep 26 ’23, which means that Fairmount Funds Management LLC is holding 1,903,833 shares at $394,500 based on the most recent closing price.

Stock Fundamentals for DNTH

Current profitability levels for the company are sitting at:

  • -34.97 for the present operating margin
  • 0.04 for the gross margin

The net margin for Dianthus Therapeutics Inc stands at -41.84. The total capital return value is set at -0.28. Equity return is now at value -42.05, with -35.44 for asset returns.

Based on Dianthus Therapeutics Inc (DNTH), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -63.01.

Currently, EBITDA for the company is -47.82 million with net debt to EBITDA at 2.8. When we switch over and look at the enterprise to sales, we see a ratio of 471.78. The receivables turnover for the company is 2.89for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.42.

Conclusion

In a nutshell, Dianthus Therapeutics Inc (DNTH) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts